<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01103206</url>
  </required_header>
  <id_info>
    <org_study_id>2009/172/HP</org_study_id>
    <nct_id>NCT01103206</nct_id>
  </id_info>
  <brief_title>Evaluation of a Cincalcet Suppression Test</brief_title>
  <official_title>Evaluation of a Parathyroid Hormone Suppression Test With Cinacalcet. Comparison: 1- With the Results of the Intravenous Calcium Suppression Test in Healthy Controls; 2- Between Healthy Controls and Patients With Primary Hyperparathyroidism.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Rouen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Institut National de la Santé Et de la Recherche Médicale, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Rouen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to compare the results of a parathyroid hormone (PTH)suppression test
      using a single oral tablet of cinacalcet in two groups of subjects: 1- a group of healthy
      adults in whom the results of the test with cinacalcet will be compared with those of the
      standardized PTH suppression test with intravenous calcium loading; 2- a group of patients
      with proven primary hyperparathyroidism in whom the results of the test with cinacalcet will
      be compared with those obtained during the same test, in healthy controls.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2010</start_date>
  <completion_date type="Actual">February 2013</completion_date>
  <primary_completion_date type="Actual">February 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Parathyroid hormone suppression test with cainacalcet</measure>
    <time_frame>Repeated PTH measurements for a period of 12 hours</time_frame>
    <description>Comparison of the plasma parathyroid hormone levels measured in healthy controls during two tests: a test using a single oral dose of cinacalcet and a test using a standardized intravenous calcium loading.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Parathyroid hormone suppression test with cinacalcet in primary hyperparathyroidism</measure>
    <time_frame>Repeated plasma Parathyroid hormone levels for a period of 12 hours</time_frame>
    <description>Comparison of the results obtained in patients with primary hyperparathyroidism during a cinacalcet suppression test with those obtained using the same test in healthy controls.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Parathyroid Hormone Suppression Test With Cinacalcet</condition>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Parathyroid hormone suppression tests using successively (each test will be separate for a two week period) an intravenous calcium loading or cinacalcet will be performed in a group of 12 healthy volunteers.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Primary hyperparathyroidism dose I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Parathyroid hormone suppression test using the first dose of cinacalcet in patients with primary hyperparathyroidism.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Primary hyperparathyroidism dose II</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Parathyroid hormone suppression test in primary hyperparathyroidism using cinacalcet (dose 2).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cinacalcet</intervention_name>
    <description>Intake of a single tablet of cinacalcet</description>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cinacalcet dose 1</intervention_name>
    <description>PTH suppression test in primary hyperparathyroidism using cinacalcet (dose 1).</description>
    <arm_group_label>Primary hyperparathyroidism dose I</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cinacalcet dose 2</intervention_name>
    <description>Parathyroid hormone suppression test in primary hyperparathyroidism using cinacalcet (dose 2).</description>
    <arm_group_label>Primary hyperparathyroidism dose II</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Control group: healthy adult (&gt;18 years), having signed informed consent, taking no
             treatment, with effective contraception in unmenopausal women, with normal clinical
             examination, with normal plasma PTH, calcium, phosphorus, 25 OH vitamin D levels, with
             normal renal function, with normal 24 hour calciuria.

          -  Primary hyperparathyroidism group: adult patients (&gt;18 years), having signed informed
             consent, with effective contraception in unmenopausal women, taking no treatment known
             to modify calcium-phosphorus status, with normal BMI, in which the diagnosis of
             primary hyperparathyroidism was confirmed on plasma PTH, calcium, phosphorus, 25 OH
             vitamin D levels, with normal renal function, with 24 hour calciuria higher than
             normal.

        Exclusion Criteria:

          -  Control group: significant medical or surgical history, creatinine clearance &lt;60
             ml/min, liver insufficiency, arterial hypertension, psychiatric disorder able to
             modify the compliance to the study, tobacco intoxication, taking a treatment known to
             modify calcium-phosphorus status, severe known allergy, pregnant women, unmenopaused
             women without contraception.

          -  Primary hyperparathyroidism group:secondary hyperparathyroidism, creatinine clearance
             &lt;60 ml/min, liver insufficiency, psychiatric disorder able to modify the compliance to
             the study, tobacco intoxication, taking a treatment known to modify calcium-phosphorus
             status, severe known allergy, pregnant women.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean Marc J Kuhn, MD</last_name>
    <role>Study Director</role>
    <affiliation>University Hospital of Rouen, France:</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Anne F Cailleux, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital of Rouen, France:</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University hospital</name>
      <address>
        <city>Rouen</city>
        <state>Haute Normandie</state>
        <zip>76031</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 12, 2010</study_first_submitted>
  <study_first_submitted_qc>April 13, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 14, 2010</study_first_posted>
  <last_update_submitted>October 15, 2013</last_update_submitted>
  <last_update_submitted_qc>October 15, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 16, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Parathyroid hormone</keyword>
  <keyword>Cinacalcet</keyword>
  <keyword>Primary hyperparathyroidism</keyword>
  <keyword>Diagnosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vision Disorders</mesh_term>
    <mesh_term>Hyperparathyroidism</mesh_term>
    <mesh_term>Hyperparathyroidism, Primary</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hormones</mesh_term>
    <mesh_term>Cinacalcet Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

